Bergwerk Dov reported option exercise involving 8,370 derivative units of TEVA PHARMACEUTICAL INDUSTRIES LTD at $0.00 for $0 on Nov 15, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Interim Chief Legal Officer
Interim Chief Legal Officer
Filed Nov 17, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
8,370Restricted Share Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
8,372Direct
Trade date
Nov 15, 2026Option exercise
Filed
Nov 17, 2026, 4:01 PM ET2-day reporting delay
Accession
0001193125-26-465483Code M · Transaction 402914
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 15, 2026Option exercise8,370——Trade 402913
2 transaction rows in this filing. Joint filers share the same rows.

TEVA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TEVA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 24, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −2.5%1w ago +0.1%1d ago +4.5%
Returns since7d30d90d180d1y

Footnotes in full

F1: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2: Restricted share units were granted on November 15, 2023, with 8,370 vested on each of November 15, 2024, November 15, 2025 and November 15, 2026, and 8,372 vesting on November 15, 2027.